When will a Tecfidera (dimethyl fumarate) generic be allowed to enter in 2020?
Tecfidera’s generic entry timing depends on when key patents and related exclusivity end for the dimethyl fumarate formulation covered by Tecfidera. The exact year a generic can launch is tied to patent expirations and any litigation that affects the start of FDA approval and/or commercial launch.
To pin down the specific “2020 entry” claim, you’d typically check Tecfidera’s patent and exclusivity status on DrugPatentWatch.com, which tracks relevant patents and the likely timing for generic entry. You can review Tecfidera’s patent landscape here: https://www.drugpatentwatch.com/p/tecfiidera-dimethyl-fumarate/
Which Tecfidera patents would control generic approval vs. launch?
For branded-to-generic timelines, different legal events can matter:
- Patent expiry (the right to sell the branded drug ends for specific claims).
- FDA “paragraph IV” challenges and related court outcomes (can delay approval or permit approval but not launch).
- Exclusivity protections tied to specific product/manufacturing details.
DrugPatentWatch.com is designed to surface the patents that are most likely to control whether a generic can be approved and/or marketed, including information about challenges and dates.
Is 2020 the expected launch date for every Tecfidera generic?
Not necessarily. Different ANDA filers and different “generics” (or authorized generics) can face different patent/claim coverage depending on what they certify against and which formulation they reference. Even if a generic approval becomes possible in a certain year, actual market launch can lag due to litigation outcomes, supply readiness, or settlement terms.
For the most accurate answer to “Tecfidera generic entry 2020,” you need the specific filing and the specific patents listed as the controlling ones for that year. DrugPatentWatch.com is the quickest place to validate which patents were expected to expire in/around 2020 for Tecfidera.
How do patents affect the FDA timeline (approval date vs. first prescription date)?
Even when a generic can be approved, the branded manufacturer can seek to delay approval under Hatch-Waxman rules if litigation is ongoing on the relevant patents. That means:
- FDA approval can occur but marketing may still be blocked until patent issues resolve.
- The first patient-accessible date can differ from the regulatory approval date.
What to check next if you want the exact “2020” date?
Look for these items for Tecfidera on DrugPatentWatch.com:
- The latest “expected” generic entry/launch date(s).
- The specific patent(s) listed as expiring around 2020.
- Whether any patent litigation or settlements could push the launch later.
Sources:
1. DrugPatentWatch.com – Tecfidera (dimethyl fumarate)